This office has provided full statistical and data management support for over 450 GOG trials and over 110,000 patient registrations. These trials include 119 Phase 3 clinical trials, 4 Phase 2/3 clinical trials, over 50 phase 1, and over 290 phase 2 trials, most of which were government funded.

Enrolled over 115,000 patients, 46,000 using full suite of proprietary software systems, captured over 2.4 million eCRFs, generated over 350,000 queries (2/3 automated), tracked over 250,000 specimens, facilitated over 17,000 electronic case reviews.

Several FDA indications for Paclitaxel, Bevacizumab, and Topotecan for Ovarian and/or Cervix cancer were based on GOG trials.